Pharmaceutical Policies under Economic Crisis: The Greek case
Journal Title: JOURNAL OF HEALTH POLICY & OUTCOMES RESEARCH - Year 2016, Vol 10, Issue 2
Abstract
Introduction: The purpose of this paper is to critically assess the Pharmaceutical reforms implemented in Greece before and during the economic crisis. The effects of the crisis are multiple in terms of GDP reduction, severe cuts of health and pharmaceutical expenditures and the deterioration of the health status of the population. However, the crisis has been a “window opportunity” to implement the long anticipated reforms in the health sector. Methods: The analysis is based on Time series data from the OECD Health data source covering the period 1970-2014. Double Logarithmic models are explored to estimate income elasticity for pharmaceutical expenditures. The value of the income elasticity in the Pre-crisis period is 1.72 the highest in Europe. The average annual growth of Pharmaceutical expenditure in the pre-crisis period was 12.3% i.e. the highest among the EU-28 countries and during the crisis this rate dropped to -8.5% the lowest among the EU-28. Results: The evolution of thePharmaceutical policies and reforms are discussed with reference to HTA, Co-payments, Claw-back and the E-Prescribing. The mixture of both demand and supply side measures resulted in a substantial reduction of pharmaceutical expenditures from 5,6 bil. Euros in 2009 to 2 bil. Euros in 2016. One of the main contributing factors to cost containment policies is the effective launching of E-prescribing. Exclusion and deprivation of citizens of effective and innovative medicinal treatments should be avoided and their access to health services and medicines should be assured. The new strategy in medicinal products should ensure good quality at affordable prices. The Greek Government, in an attempt to reach the Memorandum objective of 1 percent of GDP on pharmaceutical spending should develop incentives to promote the use of generic medicines and the cost-effective use of medicines in general Conclusions: With all its pros and cons, Greece appears to be an interesting case study to assess the success and failures of the various pharmaceutical reforms implemented.
Authors and Affiliations
Nick Yfantopoulos, Platon Yfantopoulos, John Yfantopoulos
Keywords
Related Articles
- EP ID EP192283
- DOI 10.7365/JHPOR.2016.2.1
- Views 84
- Downloads 0
Real-life treatment patterns and medication costs in patients with hypertension treated with ramipril monotherapy or ramipril loose and fixed combinations in Poland
Background: Real-World Evidence (RWE) provides insights into patient outcomes reflecting current practices under existing healthcare system conditions. Longitudinal patient data are a source of information that can be us...
European Union Legal System for Health Emergencies
Background- The aim is to analyze how the legal system in the European Union that deals with the public health emergencies in terms of organization and readiness to respond to public health emergencies. Methods - The m...
Comparator outcomes profile: need for an informed assessment of secondary outcomes for conducting post-launch observational studies in the HE&OR setting
Secondary clinical and health outcomes provide additional value and help drug molecule distinguish itself from competitor molecules. Comparator outcomes profile (COP) document in health economics and outcomes research (H...
Pharmaceutical Policies under Economic Crisis: The Greek case
Introduction: The purpose of this paper is to critically assess the Pharmaceutical reforms implemented in Greece before and during the economic crisis. The effects of the crisis are multiple in terms of GDP reduction, se...
The problem of thresholds determination in ranking classifiers applied in medical diagnostics
The paper presents the opportunity for using multi-objective optimization for the development of ranking meta-classifiers being a synthesis of simple ranking domain functions. The method of threshold determination in the...